Harvey Bale, Jr., MD, former Director-General, IFPMA
Jane Henney, MD, Former FDA Commissioner
The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?
Obligations to fund and support costly studies can extend beyond the period of market exclusivity, giving generics competitors an advantage.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial